Item 8.01 Other Events.

On April 3, 2023, OncoSec Medical Incorporated (the "Company") issued a press release announcing clinical data from the Phase 2 KEYNOTE-695 trial, which evaluated TAVO™, the Company's proprietary interleukin 12 encoding plasmid delivered by intratumoral electroporation (TAVO™-EP), in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma refractory to anti-PD-1 treatment. The full text of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits.

The following exhibits are filed herewith:

99.1 Press release dated April 3, 2023.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses